User:JZindler/sandbox-Amgen-updates

Hi there! I have a COI: Amgen is a client of my employer, Porter Novelli. Requesting some edits to this article to provide a more complete reflection of the company's history as depicted in independent, reliable sources over the years.

Intro

Update the sentence "One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980." to read "It is one of the world's largest biotechnology companies" - the information about Thousand Oaks is repetitive from the line before.

After the line ""It is one of the world's largest biotechnology companies", start a new paragraph to add a company description as follows:

Amgen discovers, develops, manufactures and delivers human therapeutics that provide clinical benefits in addressing serious diseases with unmet need. The company’s approach to drug discovery and development begins by using tools such as advanced human genetics to understand the fundamental biologic mechanisms of disease.^[1]

After "Amgen's Thousand Oaks staff in 2017 numbered 5,125 (7.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer in Ventura County", add:

Currently, Amgen has approximately 22,000 staff^[2] and a presence in approximately 100 countries and regions worldwide. The company focuses on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation.^[3]

Update the sentence "In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases" with more recent sources and information as follows:

In 2019, the company's largest selling products were Enbrel (etanercept), a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases,^[4] and Neulasta (pegfilgrastim), an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy.^[5]

Update the sentence "Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA." to include recent products, as follows:

Other marketed products include Aimovig (erenumab-aooe), AMGEVITA (adalimumab), Aranesp (darbepoetin alfa), AVSOLA (infliximab-axxq), BLINCYTO (blinatumomab), Corlanor (ivabradine), EPOGEN (epoetin alfa), EVENITY (romosozumab-aqqg), IMLYGIC (talimogene laherparepvec), KANJINTI (trastuzumab-anns), KYPROLIS (carfilzomib), MVASI (bevacizumab-awwb), NEUPOGEN (granulocyte colony-stimulating factor), Nplate (romiplostim), Otezla (apremilast), Parsabiv (etelcalcetide), Prolia (denosumab), Repatha (evolocumab), Sensipar/Mimpara (cinacalcet), Vectibix (panitumumab), and XGEVA (denosumab).

References

^ "About Amgen". Amgen. Retrieved 12 July 2022.
^ Dunleavy, Kevin (7 May 2021). "Even with the pandemic easing in the U.S., Amgen will let most employees keep working from home". Fierce Pharma. Retrieved 12 July 2022.
^ "UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-K". www.sec.gov.
^ Blankenship, Kyle (27 July 2020). "The top 20 drugs by global sales in 2019". Fierce Pharma. Retrieved 12 July 2022.
^ Hagen, Tony (4 February 2021). "Amgen Profits Get a Ride on Biosimilar Growth". The Center For Biosimilars. Retrieved 12 July 2022.

[1] "About Amgen". Amgen. Retrieved 12 July 2022.

[2] Dunleavy, Kevin (7 May 2021). "Even with the pandemic easing in the U.S., Amgen will let most employees keep working from home". Fierce Pharma. Retrieved 12 July 2022.

[3] "UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-K". www.sec.gov.

[4] Blankenship, Kyle (27 July 2020). "The top 20 drugs by global sales in 2019". Fierce Pharma. Retrieved 12 July 2022.

[5] Hagen, Tony (4 February 2021). "Amgen Profits Get a Ride on Biosimilar Growth". The Center For Biosimilars. Retrieved 12 July 2022.

[1]

[2]

[3]

[4]

[5]